申请人:Pfizer Inc.
公开号:US04371720A1
公开(公告)日:1983-02-01
Compounds having the formula ##STR1## R.sub.1 is hydrogen, benzyl or an ester moiety; Y is --CH(R.sub.2 ")CH(R.sub.2)-- or--CH(R.sub.3)CH.sub.2 --; R.sub.2 " is hydrogen or methyl; R.sub.2 is OH or X-substituted (C.sub.1-6)alkyl; R.sub.3 is OH, cyano or X-substituted (C.sub.1-3) alkyl; X is --OR.sub.6, --SR.sub.6, --S(O)R.sub.6, --S(O).sub.2 R.sub.6, --NR.sub.6 R.sub.7, --COOR.sub.7, --CONR.sub.7 R.sub.8 or oxo; with the proviso that when X is --NR.sub.6 R.sub.7, --COOR.sub.7 or --CONR.sub.7 R.sub.8, said group is located on the terminal carbon atom of R.sub.2 or R.sub.3 ; R.sub.6 is hydrogen, (C.sub.1-6)alkyl or acetyl; each of R.sub.7 and R.sub.8 is hydrogen or (C.sub.1-6)alkyl; s is an integer of 1 or 2; with the proviso that when R.sub.6 is acetyl, R.sub.7 is hydrogen and X is other than S(O)R.sub.6 or S(O).sub.2 R.sub.6 ; Z--W is alkyl, phenylalkyl or pyridylalkyl which can have an oxygen atom as part of the alkyl chain, and their use as CNS agents, antidiarrheals and antiemetics. Processes for their preparation and intermediates therefor are described.
具有以下式的化合物 ##STR1## R.sub.1 为氢、苄基或酯基团;Y 为--CH(R.sub.2 ")CH(R.sub.2)-- 或--CH(R.sub.3)CH.sub.2 --;R.sub.2 " 为氢或甲基;R.sub.2 为羟基或取代的(C.sub.1-6)烷基;R.sub.3 为羟基、氰基或取代的(C.sub.1-3)烷基;X 为--OR.sub.6、--SR.sub.6、--S(O)R.sub.6、--S(O).sub.2 R.sub.6、--NR.sub.6 R.sub.7、--COOR.sub.7、--CONR.sub.7 R.sub.8 或氧代;但当 X 为--NR.sub.6 R.sub.7、--COOR.sub.7 或--CONR.sub.7 R.sub.8 时,该基团位于 R.sub.2 或 R.sub.3 的末端碳原子上;R.sub.6 为氢、(C.sub.1-6)烷基或乙酰基;R.sub.7 和 R.sub.8 中的每一个为氢或(C.sub.1-6)烷基;s 为 1 或 2 的整数;但当 R.sub.6 为乙酰基、R.sub.7 为氢且 X 不是 S(O)R.sub.6 或 S(O).sub.2 R.sub.6 时;Z--W 为烷基、苯基烷基或吡啶基烷基,其中烷基链中可能含有氧原子,并且它们作为中枢神经系统药物、止泻药和抗恶心药。描述了它们的制备过程和中间体。